Aprea’s ovarian cancer drug candidate APR-246 gets European orphan drug status

Swedish biotech company Aprea has secured orphan drug designation from the European Medicines Agency (EMA) for its anti-cancer agent APR-246 to treat ovarian cancer.

Category One, Showcase, status, Uncategorized, What's Hot